Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis

Medical Hypotheses

Volumn 50, Issue 6, 1998, Pages 507-510

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; HYALURONIC ACID;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVIUM;

EID: 0031748965     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90272-9     Document Type: Article

References (40)

1. McCarty M F. The neglect of glucosamine as a treatment for osteoarthritis - a personal perspective. Med Hypotheses 1994; 42: 323-327.
2. Balazs E A. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet A, ed. Disorders of the Knee, 1st edn, Philadelphia: Lippincott 1974: 61-74.
3. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol 1994; 12: 75-82.
4. Balazs E A, Watson D, Duff I F, Roseman S. Hyaluronic acid in synovial fluid, I: Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967; 10: 357-376.
5. Vuorio E, Einla S, Hakkarainen S, Penttinen R. Synthesis of underpolymerised hyaluronic acid by fibroblasts cultured from rheumatoid and non-rheumatoid synovitis. Rheumatology 1982; 2: 97-102.
6. Dahl L B, Dahl I M S, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985; 44: 817-822.
7. Peyron J G, Balazs E A. Preliminary clinical assessment of sodium hyaluronate injection into human arthritic joints. Pathol Biol 1974; 22: 731-736.
8. Peyron J G. Intraarticular hyaluronan injections in the treatment of osteoarthritis: state-of-the-art review. J Rheumatol 1993; 20(suppl. 39): 10-15.
9. Goa K L, Benfield P. Hyaluronic acid: a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 1994; 47: 536-566.
10. Creamer P, Sharif M, George E et al. Intra-articular hyaluronate (HA) reduces keratan sulfate levels in osteoarthritic synovial fluid (OA). Arthritis Rheum 1992; 35(suppl.): B93.
11. Armstrong S, Read R, Ghosh P. The effects of intraarticular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol 1994; 21: 680-688.
12. Ghosh P, Holbert C, Read R, Armstrong S. Hyaluronic acid (hyaluronan) in experimental osteoarthritis. J Rheumatol 1995; 22(suppl. 43): 155-157.
13. Schiavinato A, Lini E, Guidolin D et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs, II: Morphological findings. Clin Orthop 1989; 241: 286-299.
14. Larsen N E, Lombard K M, Parent E G, Balazs E A. Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 1992; 10: 23-32.
15. Fukuda K, Dan H, Takayama M et al. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharm Exp Ther 1996; 277: 1672-1675 .
16. Yasui T, Akatsuka M, Tobetto K et al. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992; 13: 343-348.
17. Culty M, Miyake K, Kincade P W et al. The hyaluronate receptor is a member of the CD44 (HCAM) fatmily of cell surface glycoproteins. J Cell Biol 1990; 111: 2765-2774.
18. Wood D D, Ihrie E J, Hamerman D. Release of interleukin-1 from human synovial tissue in vitro. Arth Rheum 1985; 28: 853-862.
19. Pelletier J-P, Roughley P J, DiBattista J A et al. Are cytokines involved in osteoarthritic pathophysiology? Semin Arthritis Rheum 1991; 20(suppl. 2): 12-25 .
20. Pelletier J P, Martel-Pelletier J. Evidence for the involvement of interleukin 1 in human osteoarthritic cartilage degradation: protective effect of NSAID. J Rheumatol 1989; 16(suppl. 18): 19-27.
21. Hakansson L, Hallgren R, Venge P. Regulation of granulocyte function of hyaluronic acid in vitro and in vivo: effects on phagocytosis, locomotion, and metabolism. J Clin Invest 1980; 66: 298-305.
22. Forrester J V, Balazs E A. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 1980; 40: 435-446.
23. Forrester J V, Wilkinson P C. Inhibition of leukocyte locomotion by hyaluronic acid. J Cell Sci 1981; 48: 315-331.
24. Tamoto K, Tada M, Shimada S et al. Effects of high-molecular-weight hyaluronates on the function of guinea pig polymorphonuclear leukocytes. Semin Arthritis Rheum 1993; 22(suppl. 1): 4-8.
25. Pisko E, Turner R A, Soderstrom L P, Panetti M. Inhibition of neutrophil phagocytosis and enzyme release by hyaluronic acid. Clin Exp Rheumatol 1983; 1: 41-44.
26. 14C] arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 1992; 60: 79-84.
27. Smith M M, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987; 7: 113-122.
28. Brown T J, Laurent U B G, Fraser J R E. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol 1991; 76: 125-134.
29. Fraser J R E, Kimpton W G, Pierscionek B K, Cahill R N P. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observation with experimental arthritis in sheep. Semin Arthritis Rheum 1993; 22(suppl. 1): 9-17.
30. Rodén L. Effect of hexosamines on the synthesis of chondroitin sulphuric acid in vitro. Arkh Kemi 1956; 10: 345-352.
31. Karzel K, Domenjoz R. Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycane metabolism of fibroblast cultures. Pharmacology 1971; 5: 337-345.
32. Kim J J, Conrad H E. Effect of D-glucosamine concentration on the kinetics of mucopolysaccharide biosynthesis in cultured chick embryo vertebral cartilage. J Biol Chem 1974; 249: 3091-3097.
33. Vidal y Plana R R, Bizzarri D, Rovati AL. Articular cartilage pharmacology, I: In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Commun 1978; 10: 557-569.
34. McCarty M F. Glucosamine for wound healing. Med Hypotheses 1996; 47: 273-275.
35. Carlozzi M, Iczzoni D G. Facilitating healing of body surface wound by intravenous administration of N-acetylglucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine. United States Patent #3,232,836, February 1, 1966.
36. Hardingham T E, Muir H. Hyaluronic acid in cartilage and proteoglycan aggregation. Biochem J 1974; 139: 565-581.
37. Hascall U C, Heinegard D. Aggregation of cartilage proteoglycans, I: The role of hyaluronic acid. J Biol Chem 1974; 249: 4232-4241.
38. Thonar E J-M A, Sweet M B E, Immelman A R, Lyons G. Hyaluronate in articular cartilage: age-related changes. Calcif Tiss Res 1978; 26: 19-21.
39. Manicourt D H, Pita J C. Progressive depletion of hyaluronic acid in early experimental osteoarthritis in dogs. Arth Rheum 1988; 31: 538-544.
40. Tyler J A. Articular cartilage cultured with catabolin (pig interleukin-1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J 1985; 227: 869-878.